Last reviewed · How we verify
IMP4927
IMP4927 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage infiltration and activation in the tumor microenvironment.
IMP4927 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage infiltration and activation in the tumor microenvironment. Used for Advanced solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | IMP4927 |
|---|---|
| Sponsor | Impact Therapeutics, Inc. |
| Drug class | CSF1R inhibitor |
| Target | CSF1R (Colony-Stimulating Factor 1 Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CSF1R inhibition decreases the recruitment and survival of tumor-associated macrophages (TAMs), which are immunosuppressive cells that promote tumor growth and metastasis. By depleting or reprogramming these macrophages, IMP4927 aims to enhance anti-tumor immunity and improve the efficacy of checkpoint inhibitors or other immunotherapies.
Approved indications
- Advanced solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |